Product Advantages

Every year more than 4 million new cancer cases are diagnosed in China, and targeted therapy and immunotherapy are booming. Yet single-omics genetic testing yields a low benefit rate: the suitability and response rates of targeted therapy are only 8.33% and 4.90%. By contrast, multi-omics technology integrates gene, protein and metabolite testing to deliver individualized solutions, effectively raising the suitability rate of targeted drugs to 84%.

Applicable Population

All patients with solid tumors; elderly or frail patients who cannot or do not wish to receive conventional radiotherapy or chemotherapy; patients relying on targeted or immunotherapy drugs to prolong survival; and clinical patients with very small biopsy samples.

Product Advantages

ProteinT has independently developed a recurrence risk model for Stage I lung cancer that calculates a patient’s recurrence score with a sensitivity and specificity of up to 54% and 95% respectively, precisely assessing recurrence risk and delivering clear clinical benefit to patients.

Applicable Population

This test is intended for patients with Stage I NSCLC (Stage IA and Stage IB) after surgical resection.

Technical Advantages

Whole-molecular signal recognition: NMR technology captures the overall information of the vast array of biomolecules in blood rather than relying on a single indicator.

AI deep-learning interpretation: a Transformer deep-learning model identifies molecules and the high-dimensional coupling relationships among them.

Purely molecular data-driven: the model analyzes blood molecular signals alone, without depending on other clinical information.

Algorithm-native: the highly standardized, uninterrupted NMR signal provides a “zero-noise” computational data resource for the AI model.

Indications / Application Scenarios

Screening of common cancers and cardiovascular and cerebrovascular diseases.

Screening of high-risk populations and differentiation of benign from malignant diseases.

Proactive screening and health management for the general population.

Disease course monitoring.

Product Matrix

Technical Advantages

Precision detection: Unaffected by lesion site, disease stage, age or gender; sensitivity up to 78% and specificity above 97%, reducing missed diagnoses and misdiagnoses.

Comprehensive coverage: A single test predicts the risk of the six cancers with the highest incidence and mortality rates in China.

Safe and non-invasive: Only 2 mL of peripheral blood is needed for dynamic clinical monitoring — non-invasive, painless and free of radiation hazards.

Early warning: Detects disease before clinical symptoms appear, enabling earlier intervention to improve patient survival and reduce treatment costs.

Applicable Population

People aged 40 and above (inclusive) are advised to undergo regular, early cancer risk screening.

Product Advantages

Applicable Population

Populations at high risk of common cancers and healthy individuals willing to undergo non-invasive early screening.

Application Scenarios